Maria C. Schneeweiss

Apr 2, 2024 | onlinelibrary.wiley.com | Maria C. Schneeweiss |Arash Mostaghimi |Stephanie E Chiuve |Sebastian Schneeweiss

CONFLICT OF INTEREST STATEMENT Dr. Lin, Dr. Anand, Ms. Schoder, and Ms. Oduol have no financial disclosures to report. Dr. M. Schneeweiss has received a research grant to the Brigham and Women's Hospital from UCB pharma for work unrelated to the topic of this study. Dr. Mostaghimi reports personal fees from Pfizer, Digital Diagnostics, 3Derm, AbbVie, Bioniz, Concert, Lilly, Hims, and participation in clinical trials with Incyte, Aclaris, Concert, and Lilly outside the submitted work.

Aug 22, 2023 | dialnet.unirioja.es | Maria C. Schneeweiss |Timothy Savage |Richard Wyss |Yinzhu Jin

Risk of Infection in Children With Psoriasis Receiving Treatment With Ustekinumab, Etanercept, or Methotrexate Before and After Labeling ExpansionAutores: Maria C. Schneeweiss, Timothy J. Savage, Richard Wyss, Yinzhu Jin, Katharina Schoder, Joseph F. Merola, Robert Sidbury, Theresa Oduol, Sebastian Schneeweiss, Robert J. GlynnLocalización: JAMA Dermatology, ISSN 2168-6068, Vol. 159, Nº. 3, 2023, págs.

Jun 7, 2023 | jamanetwork.com | Maria C. Schneeweiss |Joseph F. Merola |Richard Wyss |Jonathan I. Silverberg

Key PointsQuestion  What is the background rate of venous thromboembolism (VTE) in patients with bullous pemphigoid in the US? Findings  In this cohort study including 2654 patients with bullous pemphigoid and 26 814 comparator patients, a large-scale analysis of US claims data found a 2-fold increased risk of clinical VTE events in patients with bullous pemphigoid compared with similar patients without the disease.